IL131925A0 - Insulin-like growth factor agonist molecules - Google Patents

Insulin-like growth factor agonist molecules

Info

Publication number
IL131925A0
IL131925A0 IL13192598A IL13192598A IL131925A0 IL 131925 A0 IL131925 A0 IL 131925A0 IL 13192598 A IL13192598 A IL 13192598A IL 13192598 A IL13192598 A IL 13192598A IL 131925 A0 IL131925 A0 IL 131925A0
Authority
IL
Israel
Prior art keywords
insulin
growth factor
agonist molecules
factor agonist
molecules
Prior art date
Application number
IL13192598A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL131925A0 publication Critical patent/IL131925A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13192598A 1997-04-04 1998-03-31 Insulin-like growth factor agonist molecules IL131925A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/825,852 US6121416A (en) 1997-04-04 1997-04-04 Insulin-like growth factor agonist molecules
PCT/US1998/006514 WO1998045427A2 (en) 1997-04-04 1998-03-31 Insulin-like growth factor agonist peptides

Publications (1)

Publication Number Publication Date
IL131925A0 true IL131925A0 (en) 2001-03-19

Family

ID=25245064

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13192598A IL131925A0 (en) 1997-04-04 1998-03-31 Insulin-like growth factor agonist molecules

Country Status (13)

Country Link
US (16) US6121416A (de)
EP (2) EP0972020B1 (de)
JP (1) JP4562814B2 (de)
AT (1) ATE224951T1 (de)
AU (1) AU732989B2 (de)
CA (1) CA2286264A1 (de)
DE (1) DE69808258T2 (de)
DK (1) DK0972020T3 (de)
ES (1) ES2183344T3 (de)
HK (1) HK1047755A1 (de)
IL (1) IL131925A0 (de)
PT (1) PT972020E (de)
WO (1) WO1998045427A2 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7885697B2 (en) 2004-07-13 2011-02-08 Dexcom, Inc. Transcutaneous analyte sensor
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
IL143834A0 (en) 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
DE60016560T2 (de) 1999-01-06 2005-12-15 Genentech, Inc., South San Francisco Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
US20030224017A1 (en) * 2002-03-06 2003-12-04 Samal Siba K. Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
CA2389575A1 (en) * 1999-10-29 2001-05-10 Oregon Health Sciences University Modulation of neuroendocrine differentiation by protein 25.1
JP2003528149A (ja) 2000-03-24 2003-09-24 ジェネンテック・インコーポレーテッド 軟骨性疾患の治療のためのインスリンの使用
DE60133271T2 (de) * 2000-05-16 2009-04-23 Genentech, Inc., South San Francisco Behandlung von knorpelerkrankungen
FR2810675B1 (fr) * 2000-06-22 2002-09-27 Pf Medicament Construction modifiee en aval du codon d'initiation pour la surexpression de proteines recombinantes
DE60143858D1 (de) * 2000-11-28 2011-02-24 Premacure Ab Reduzierung DES RISIKOS FÜR KOMPLIKATIONEN BEI FRÜHGEBURTEN
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
EP1772464B1 (de) 2001-02-09 2009-08-12 Genentech, Inc. Verfahren zur Identifizierung von indirekten IGF-1-Agonisten
CA2438641A1 (en) 2001-02-15 2002-08-22 King Pharmaceuticals, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US6790672B2 (en) * 2001-02-19 2004-09-14 Board Of Regents The University Of Texas System Encoded molecular sieve particle-based sensors
WO2002072780A2 (en) 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
US6841386B2 (en) 2001-04-10 2005-01-11 Viacell, Inc. Modulation of primary stem cell differentiation using an insulin-like growth factor binding protein
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20100247483A1 (en) * 2001-11-13 2010-09-30 Tran Loi H Therapeutic agent composition and method of use
US7232798B2 (en) 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
WO2003041655A2 (en) * 2001-11-13 2003-05-22 Loi Tran Therapeutic agent composition and method of use
PL210412B1 (pl) 2002-05-24 2012-01-31 Schering Corp Izolowane przeciwciało anty-IGFR lub jego fragment, kompozycja farmaceutyczna, zastosowanie, kwas nukleinowy, zrekombinowany wektor, komórka gospodarza, kompleks, polipeptyd i sposób jego wytwarzania
WO2003103608A2 (en) * 2002-06-11 2003-12-18 The Burnham Institute Neuroprotective synergy of erythropoietin and insulin-like growth factor
US7118877B2 (en) * 2002-07-08 2006-10-10 Wyeth Caspase 9 activation and uses therefor
US7648957B2 (en) * 2002-09-04 2010-01-19 Dsm Ip Assets B.V. Nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
DE60217188T2 (de) * 2002-09-06 2007-10-04 Telefonaktiebolaget Lm Ericsson (Publ) Zusammengesetzter leistungsverstärker
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
US20060128615A1 (en) * 2002-09-18 2006-06-15 Pierrette Gaudreau Ghrh analogues
EP1560933A4 (de) * 2002-11-14 2007-11-21 Wyeth Corp Verfahren und zusammensetzungen zur behandlung neurologischer erkrankungen
US7273788B2 (en) * 2003-05-21 2007-09-25 Micron Technology, Inc. Ultra-thin semiconductors bonded on glass substrates
EP2093570A1 (de) * 2003-06-06 2009-08-26 Genentech, Inc. Modulierung der Interaktion zwischen HGF-beta-Kette und c-Met
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
ATE536186T1 (de) 2003-09-12 2011-12-15 Tercica Inc Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
CA2541015A1 (en) * 2003-10-03 2005-04-14 Genentech, Inc. Igf binding proteins
WO2005047512A2 (en) 2003-11-12 2005-05-26 Shering Corporation Plasmid system for multigene expression
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
US20050233960A1 (en) 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
CA2560278C (en) * 2004-03-19 2012-11-20 Matthew Baker Modified bouganin proteins, cytotoxins and methods and uses thereof
WO2006127694A2 (en) 2004-07-13 2006-11-30 Dexcom, Inc. Analyte sensor
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
MX2007006640A (es) 2004-12-03 2007-06-19 Schering Corp Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
AU2006236637B2 (en) * 2005-04-15 2012-09-06 Merck Sharp & Dohme Corp. Methods and compositions for treating or preventing cancer
WO2006138315A2 (en) * 2005-06-15 2006-12-28 Schering Corporation Anti-igf1r antibody formulations
US7695928B2 (en) 2006-04-10 2010-04-13 Genentech, Inc. Disheveled PDZ modulators
WO2008130315A1 (en) 2007-04-18 2008-10-30 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity
JP2010536880A (ja) 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法
US8591455B2 (en) 2008-02-21 2013-11-26 Dexcom, Inc. Systems and methods for customizing delivery of sensor data
US11730407B2 (en) 2008-03-28 2023-08-22 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8682408B2 (en) 2008-03-28 2014-03-25 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8583204B2 (en) 2008-03-28 2013-11-12 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US9238080B2 (en) 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
CN103270045A (zh) 2010-10-20 2013-08-28 霍夫曼-拉罗奇有限公司 用于调控wnt途径的方法和组合物
MX355128B (es) 2011-10-14 2018-04-06 Genentech Inc Péptidos inhibidores de bace1 y uso de los mismos para el tratamiento de enfermedades o trastornos neurológicos.
EP2766034B1 (de) 2011-10-14 2018-06-13 F. Hoffmann-La Roche AG Zymogen-aktivatoren
EP3355907B1 (de) 2015-10-02 2021-01-20 Silver Creek Pharmaceuticals, Inc. Bispezifische therapeutische proteine zur gewebereparatur
IL273174B2 (en) 2017-09-11 2024-12-01 Shire Human Genetic Therapies Insulin-like growth factor-1 (igf-1) for use in treating chronic lung diseases
BR112020023252A2 (pt) 2018-05-15 2021-02-23 Lloyd Hung Loi Tran composição do agente terapêutico e método de uso para tratamento de deficiência cognitiva leve, depressão e distúrbios psicológicos.
US20210008172A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same
GB201913196D0 (en) 2019-09-12 2019-10-30 Univ Newcastle Culture method
PT4228676T (pt) 2020-10-19 2025-01-24 Oak Hill Bio Ltd Composições adequadas para utilização em recém-nascidos
DE102021122096A1 (de) 2021-08-26 2023-03-02 Forschungsinstitut für Nutztierbiologie IGF-1, IGFBP-2 und Insulin umfassende Zusammensetzungen und ihre Verwendung
WO2023139115A1 (en) 2022-01-19 2023-07-27 Oak Hill Bio Limited Compositions and methods for reducing oxidation of igf‐1/igfbp
CN117589998B (zh) * 2023-10-09 2025-11-18 融智生物科技（青岛）有限公司 胰岛素样生长因子i变体的定量检测试剂盒
CN117347626B (zh) * 2023-12-06 2024-03-12 安徽惠邦生物工程有限公司 人胰岛素样生长因子结合蛋白-1化学发光免疫分析试剂盒及其制备方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3721252A (en) * 1971-04-01 1973-03-20 Catheter And Instr Corp Spring guide washer
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
PH23185A (en) 1983-06-13 1989-05-29 Scheindel Ass Inc Pressure operated dispensing container
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
EP0134094B1 (de) 1983-08-15 1987-05-27 AMP INCORPORATED (a New Jersey corporation) Elastischer Einpressstift für elektrische Leiterplatten
US5077276A (en) * 1985-08-22 1991-12-31 Gropep Pty Ltd Growth factor
SE8505922D0 (sv) * 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
EP0308500B1 (de) * 1987-04-06 1993-06-16 Celtrix Pharmaceuticals, Inc. Menschliche somatomedin-träger-protein-untereinheiten und verfahren zu ihrer herstellung
AU607209B2 (en) * 1987-04-23 1991-02-28 Monsanto Technology Llc Secretion of insulin-like growth factor-i in e. coli
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5470828A (en) * 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
ATE116335T1 (de) * 1987-12-24 1995-01-15 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
DE68905203T2 (de) * 1988-02-05 1993-07-22 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
DK131988A (da) * 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ATE132164T1 (de) * 1988-04-12 1996-01-15 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) * 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
EP0379338A3 (de) * 1989-01-17 1991-07-24 Merck & Co. Inc. Menschlicher insulinähnlicher Wachstumsfaktor und seine Herstellung in Hefe
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5593844A (en) * 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
DK1820858T3 (da) * 1991-03-01 2009-11-02 Dyax Corp Kimært protein omfatende mikroprotein med to eller flere disulfidbindinger og udförelsesformer deraf
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
CA2114251C (en) * 1991-08-01 2007-11-06 Peter Gluckman Igf-1 to improve the neural condition
US6310040B1 (en) * 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
HU217543B (hu) * 1992-06-12 2000-02-28 Albert Einstein College Of Medicine Of Yeshiva University Eljárás perifériás neuropátia kezelésére és megelőzésére alkalmas gyógyászati készítmények előállítására, valamint inzulinszerű növekedési faktor I-et és kemoterápiás szert tartalmazó gyógyászati készítmények
NZ255461A (en) * 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
WO1994016722A1 (en) * 1993-01-25 1994-08-04 The Beth Israel Hospital Association Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
WO1994016723A2 (en) * 1993-01-29 1994-08-04 Synergen, Inc. Wound healing composition
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
AU683121B2 (en) * 1993-12-23 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
SG55069A1 (en) * 1993-12-23 1998-12-21 Novo Nordisk As Compounds with growth hormone releasing properties
SE9402370D0 (sv) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
SE9501472D0 (sv) * 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) * 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
KR100543190B1 (ko) * 1995-05-26 2006-06-23 떼라떼끄놀로지 인코퍼레이티드 향상된생물학적효능을갖는키메라성지방체-프로-지알에프유사체
ATE254138T1 (de) * 1995-06-07 2003-11-15 Ortho Pharma Corp An den erythropoietin-rezeptor bindende zusammensetzungen und peptide
YU34196A (sh) * 1995-06-07 1999-03-04 Glaxo Group Limited Peptidi i jedinjenja koja se vezuju za receptor
ATE390439T1 (de) * 1995-06-07 2008-04-15 Glaxo Group Ltd An einem thrombopoietin rezeptor bindende peptide und zusammensetzungen
US5958872A (en) * 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
EP0854884A1 (de) * 1996-04-17 1998-07-29 Neurocrine Biosciences, Inc. Inhibitoren von liganden der insulin-ähnlichen faktor bindenden proteine und methoden für ihre verwendung
US6402715B2 (en) 1996-04-25 2002-06-11 Karl Storz Gmbh & Co. Kg Surgical instrument system
AU7891098A (en) 1996-12-27 1998-07-31 Daiichi Pharmaceutical Co., Ltd. Method for elevating the concentration of free insulin-like growth factor
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof

Also Published As

Publication number Publication date
US6713451B1 (en) 2004-03-30
US6121416A (en) 2000-09-19
PT972020E (pt) 2003-02-28
DE69808258T2 (de) 2003-09-18
JP2002510194A (ja) 2002-04-02
WO1998045427A2 (en) 1998-10-15
US6683053B1 (en) 2004-01-27
EP1251137A2 (de) 2002-10-23
DE69808258D1 (de) 2002-10-31
US6693078B1 (en) 2004-02-17
US6632794B1 (en) 2003-10-14
US6251865B1 (en) 2001-06-26
EP1251137A3 (de) 2003-04-16
US6949349B1 (en) 2005-09-27
JP4562814B2 (ja) 2010-10-13
US6677305B1 (en) 2004-01-13
AU6947098A (en) 1998-10-30
ES2183344T3 (es) 2003-03-16
EP0972020A1 (de) 2000-01-19
US6645775B1 (en) 2003-11-11
DK0972020T3 (da) 2003-02-03
US6620789B1 (en) 2003-09-16
US6680298B1 (en) 2004-01-20
CA2286264A1 (en) 1998-10-15
WO1998045427A3 (en) 1999-01-07
US6716586B1 (en) 2004-04-06
US6689751B1 (en) 2004-02-10
ATE224951T1 (de) 2002-10-15
US6608031B1 (en) 2003-08-19
US6693079B1 (en) 2004-02-17
AU732989B2 (en) 2001-05-03
HK1047755A1 (en) 2003-03-07
EP0972020B1 (de) 2002-09-25
US6635619B1 (en) 2003-10-21

Similar Documents

Publication Publication Date Title
IL131925A0 (en) Insulin-like growth factor agonist molecules
CANALIS Effect of growth factors on bone cell replication and differentiation
HUP0003173A3 (en) Use of glp-1 or analogs for preparing pharmaceutical compositions useful in treatment of myocardial infarction
IL95118A0 (en) Polypeptide derivatives,their preparation and pharmaceutical compositions containing them
MX9707487A (es) Uso de composiciones que comprenden compuestos efectivos biologicamente estabilizados.
BG103297A (en) Aralkyl and aralkyliden heterocyclic lactams and imides
IL113812A (en) Copolymer-1 pharmaceutical compositions containing it and its use
PL338438A1 (en) Cosmetic composition containing siloxane-based polyamides as thickening agents
EE200100649A (et) A-beeta peptiidi kompositsioonid ja meetodid nende valmistamiseks
WO2000002916A3 (en) PEPTIDE COMPOSITIONS MIMICKING TGF-β ACTIVITY
MY104992A (en) Composition inducing a binding.
DE69838730D1 (de) Zusammensetzung zur zahnbeschichtung
AU2001263215A1 (en) Method for treating cartilage disorders
AU6207290A (en) Gum composition containing protein macrocolloids
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
WO2000042031A3 (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
EP0992584A3 (de) Gereinigte Säugetier FLT3 Liganden und deren Agonisten und Antagonisten
HU9300192D0 (en) Polypeptide compounds promoting growth hormone emission
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
WO2002034916A3 (en) Novel mutant igbp-3 molecules that do not bind to igfs, but retain their ability to functionally bind igfbp-3 receptor
FI972170A0 (fi) Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, näitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö
IL129359A0 (en) Bi-aromatic compounds bound by a heteroethynylene radical and pharmaceutical and cosmetic compositions containing same
EE05182B1 (et) Asendatud homopiperidlbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
HUP9904547A3 (en) Benzoxazole derivative with an affinity to binding sites of amino acid receptors and pharmaceutical compositions containing the same
EP0588177A3 (en) An interferon-alpha/beta binding protein, its preparation and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees